Today, five new Class 1 drugs were approved clinically from Bayer, Novarma, Jesinta and other companies.

1, Bayer: finerenone tablet action mechanism / target: salt corticosteroid antagonist Finerenone (BAY94-8862) is a research nonsteroidal selective salt corticosteroid inhibitor antagonist (MRA), which can reduce the harmful effects of salt corticosteroids (MR) overactivation.
overactivation of salt corticosteroids is a major driver of kidney and heart damage.
previously, Finerenone had been granted fast-track status by the FDA.
July, the product reached its end point in Phase 3 clinical trials for patients with chronic kidney disease (CKD) with type 2 diabetes.
addition of the product to standard care can delay the first occurrence of kidney failure, reduce the risk of death from kidney disease, and slow down the rate of lephal filtration (eGFR).
is the first clinical approval in China for finerenone, which is intended to be developed to treat heart failure in the left ≥ 40% of the blood score.
2, Novartic: Leizhu single anti-injection mechanism / target: anti-VEGF drug Leizhu monoantigen is a very small molecular weight of anti-VEGF drug, without Fc fragments, easy to penetrate the entire retina layer, through the cell gap, all reach the vein blood vessels, accurate and rapid access to the lesions area.
the drug has been approved for use in more than 100 countries and regions around the world since it went on sale in 2006.
Currently, the product has been approved for market in China, and the adaptive disorders include wet geriatric macular degeneration, retinal vein blockage secondary macular edema, diabetic macular edema, vision impairment caused by new blood vessels in the vein membrane, etc.
The Leizhu monoantigen resistance has been approved clinically in China and is intended to be developed for the treatment of moderate to severe non-proliferative diabetic retinal lesions (NPDRs) and moderate to severe proliferative diabetic retinal lesions (PDRs).
3, Ganley Pharmaceuticals: ASC41 tablet mechanism of action / target: THR-β astration CDE official website shows that the ASC41 tablets declared by Ganlai Pharmaceuticals obtained the implied permission of clinical trials, intended to be developed for the treatment of adult non-alcoholic fatty hepatitis.
previously, ASC41 capsules jointly declared by Ganlay Pharmaceuticals and Goliath Pharmaceuticals had been approved for clinical trials of NASH adaptations.
According to a Goliath press release, ASC41 is an oral thyroid hormone β order agonist (THR-beta agonist), which is expected to be used in a joint treatment with Goliath's other innovative drug, the fatty acid synthase inhibitor ASC40.
4, Esindawei: AST-3424 mechanism of action / target: Broadspectral Targeting Drug According to Essindawei press release, AST-3424 is the world's first small molecule new drug, with a unique mechanism of action and high targeting, selective killing of AKR1C3 overexposed tumor cells, but the impact on normal cells is small or no impact.
the properties of target activation and abundance in this highly selective tumor cell, the ability and safety of AST-3424 have been greatly improved.
documents show that akR1C3 is highly expressed in up to 15 kinds of solid tumors and blood tumors, especially in hepatocellular carcinoma, hyperlytic prostate cancer and other existing drug-resistant and difficult-to-treat tumor cells.
AST-3424 was approved by the Blood Tumor Phase 1B/2 clinical trial to be developed for patients with relapsed or recurring acute lymphoblastic leukemia.
5, JesInda: Injection E6201 action mechanism / target: MEK1/FLT3 dual-target inhibitor E6201 is a dual-target inhibitor that can target MEK1 and FLT3 at the same time.
preclinical results show that the product has a strong ability to penetrate the blood-brain barrier.
MEK is a silk rift active protein kinase/extracellular signal-regulating kinase.
RAS/RAF/MEK/ERK signaling path is one of the most important in-cell signal transducting paths, and MEK is a key member of this signaling path, regulating several key cellular biology activities, including proliferation, differentiation, migration, survival, and angiogenesis.
2018, Jesinta and Spirita Oncology will work together to develop E6201 worldwide.
E6201 has been approved for clinical trials in China to develop advanced solid tumors associated with brain metastasis for RAS/BRAF/MEK gene mutations.
CDE website, this is the first time the product has been approved clinically in China.
Reference Center of the State Drug Administration of China. Retrieved Aug 11,2020, from [2]【】AST-3424NMPAIB/II. Retrieved Aug 10, 2020, from Esindawei Pharmaceuticals s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients With Kidney Chronic Disease and Type 2 Diabetes. Retrieved July 9, 2020, from s4 snr® entered the age of full adaptability and was approved for CNV (secondary to PM and other causes) adaptation . Retrieved November 27, 2018, from Novart Group Officer Micro s.5. Retrieved December 20, 2018. From.